Cantor Fitzgerald Reiterates Overweight Rating on AbCellera Biologics (ABCL)
July 17, 2026 9:55 AM
Cantor Fitzgerald analyst Steve Seedhouse reiterated an Overweight rating and $11.00 price target on AbCellera Biologics (NASDAQ: ABCL).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
